Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%. At ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Novavax stock took a hit in mid-October after the FDA ...